MetaCap

Schrodinger (SDGR) vs Zymeworks (ZYME)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Schrodinger (SDGR) has outperformed Zymeworks (ZYME) over the past year, gaining 39.2% versus a gain of 8.8%. Over five years, ZYME leads with a +34.1% price change compared with -42.0% for SDGR. Zymeworks is the larger company by market cap ($1.81 billion vs $1.72 billion), about 1.1 times the size.

Schrodinger converts more of its revenue into profit, with a net margin of -40.4% versus -76.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

SDGR+39.22%ZYME+8.83%
+110%+35%-40%
Nov 21, 20251 yearNov 20, 2026
SDGR-43.80%ZYME+31.95%
+56%-13%-82%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

SDGR versus ZYME key metrics
MetricSDGRZYME
Share price$22.93$26.14
Market cap$1.72B$1.81B
1-day change-12.95%-2.68%
YTD return+28.24%-0.72%
1-year return+39.22%+8.83%
5-year return-42.01%+34.05%
P/E ratio (TTM)—49.32
Forward P/E—54.95
EPS (TTM)$-0.79$0.53
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$255.87M$105.97M
Revenue growth (YoY)+23.29%+38.87%
Net income (latest FY)$-103.27M$-81.13M
Gross margin55.74%—
Operating margin-65.23%-87.34%
Net margin-40.36%-76.56%
52-week high$34.00$31.97
52-week low$10.95$21.52
Distance from 52-week high-32.56%-18.24%
Analyst consensusbuystrong_buy
Avg. price target upside+46.40%+65.61%
Average volume2.08M1.09M
Shares outstanding65.91M68.70M
Employees850279
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SDGR has outperformed ZYME by 30.4 percentage points over the past year.
  • Schrodinger is more profitable, keeping -40.4 cents of every revenue dollar as net income versus -76.6 cents for Zymeworks.
  • Zymeworks grew revenue faster in its latest fiscal year (+38.87% vs +23.29%).

About Schrodinger

SDGR stock →

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery.

Health Care · Biotechnology: Pharmaceutical Preparations · 850 employees

About Zymeworks

ZYME stock →

Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform.

Health Care · Biotechnology: Pharmaceutical Preparations · 279 employees

SDGR vs ZYME FAQ

Which is bigger, Schrodinger or Zymeworks?

Zymeworks (ZYME) is larger, with a market capitalization of $1.81B compared with $1.72B for Schrodinger (SDGR).

Which stock has performed better over the past year, SDGR or ZYME?

SDGR returned +39.22% over the past 12 months, compared with +8.83% for ZYME (price return, excluding dividends). Past performance does not predict future results.

Are Schrodinger and Zymeworks in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons